State-of-the-art treatment of metastatic renal cell carcinoma

por Heng, D.Y.C., Kollmannsberger, C.
Publicado 2009

Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma

por Delea, T E, Khuu, A, Heng, D YC, Haas, T, Soulières, D
Publicado 2012

Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma

por Toh, C-K, Heng, D, Ong, Y-K, Leong, S-S, Wee, J, Tan, E-H
Publicado 2005

Ethnicity modifies the relation between fasting plasma glucose and HbA(1c) in Indians, Malays and Chinese

por Venkataraman, K, Kao, S L, Thai, A C, Salim, A, Lee, J J M, Heng, D, Tai, E S, Khoo, E Y H
Publicado 2012

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

por Kaymakcalan, M D, Je, Y, Sonpavde, G, Galsky, M, Nguyen, P L, Heng, D Y C, Richards, C J, Choueiri, T K
Publicado 2013

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients

por Wang, Y, Choueiri, T K, Lee, J-L, Tan, M-H, Rha, S Y, North, S A, Kollmannsberger, C K, McDermott, D F, Heng, D Y C
Publicado 2014

Tracking the mental health of a nation: prevalence and correlates of mental disorders in the second Singapore mental health study

por Subramaniam, M., Abdin, E., Vaingankar, J. A., Shafie, S., Chua, B. Y., Sambasivam, R., Zhang, Y. J., Shahwan, S., Chang, S., Chua, H. C., Verma, S., James, L., Kwok, K. W., Heng, D., Chong, S. A.
Publicado 2019

Management of inpatients exposed to an outbreak of severe acute respiratory syndrome (SARS)()

por Tan, Y.-M., Chow, P.K.H., Tan, B.-H., Kurup, A., Tan, B.K.T., Tan, F.L.S., Seldrup, J., Heng, D.M.K., Ang, B., Green, J., Wong, C.-Y., Soo, K.-C.
Publicado 2004

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

por Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., Scher, H. I.
Publicado 2016

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

por Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Publicado 2014

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

por Harshman, L.C., Drake, C.G., Haas, N.B., Manola, J., Puligandla, M., Signoretti, S., Cella, D., Gupta, R.T., Bhatt, R., Van Allen, E., Lara, P., Choueiri, T.K., Kapoor, A., Heng, D.Y.C., Shuch, B., Jewett, M., George, D., Michaelson, D., Carducci, M.A., McDermott, D., Allaf, M.
Publicado 2017